How treatments affect people recently diagnosed with follicular lymphoma. A study over time

Submission date 19/09/2025	Recruitment status Recruiting	[X] Prospectively registeredProtocol		
Registration date	Overall study status Ongoing Condition category Cancer	Statistical analysis plan		
21/10/2025		☐ Results		
Last Edited		Individual participant data		
13/11/2025		[X] Record updated in last year		

Plain English summary of protocol

Background and study aims

PETReA Plus will enrol all newly diagnosed follicular lymphoma patients receiving any first treatment as part of their normal care. This is an observational study which will collect data during the clinical care of the study participants. Except for Quality of Life (QOL) questionnaires provided as Patient Reported Outcome Measures (PROMs), no extra tests or assessments will be carried out over and above standard care. The study aims to collect all the required information during the participants' planned clinic visits, where available.

Who can participate?

Adult patients aged 18 years or older with Grade 1, 2, 3A or 3B follicular lymphoma (FL), or de novo transformed FL, who have had a diagnostic biopsy within the last 6 months, are planned for any first-line treatment or initial watch and wait, and can provide written informed consent.

What does the study involve?

Routinely collected information can be taken from the participant's medical notes into the case report form once the participant has consented. Data will be collected from the participants before treatment starts, at the end of treatment and during a follow-up period (6 months +/- 2 months). There are no investigational treatments, extra risks or benefits to taking part in the study. Doctors are asked to offer participation in the PETReA Plus study to all patients who are not in the PETReA trial for as long as this remains open and thereafter to all newly diagnosed FL patients, including those participating in another CTIMP/non-CTIMP trial at local PI discretion, as long as this doesn't impact the PETReA Plus study or eligibility/conduct of the other trial. Data from the PETReA Plus study will be collected along with data from the PETReA trial to produce a combined dataset of up to 1500 participants that could provide more information on people with high tumour burden symptomatic FL who normally have a poor chance of survival.

If willing, PETReA Plus participants will also be invited to consent to share their data with the Follicular Lymphoma Foundation Registry, for an international, observational study in follicular lymphoma, which will collect data from previously treated and untreated patients to improve how quickly new treatments are made available and to standardise treatment and care for

patients across all clinics and hospitals. If willing, participants can also consent at a later date for the future collection of their routinely collected tumour tissue for future ethically approved research. These would be stored at the UK Blood Cancer Biobank.

What are the possible benefits and risks of participating? There are no benefits/risks to the participant if they take part in the study.

Where is the study run from? University of Liverpool, UK.

When is the study starting and how long is it expected to run for? September 2024 to October 2029. The study is expected to begin enrolling participants in November 2025 and will conclude enrollment in February 2028.

Who is funding the study?

- 1. The Follicular Lymphoma Foundation
- 2. Blood Cancer UK
- 3. The Joyce & Norman Freed Charitable Trust

Who is the main contact? PETReA Plus Trial Manager, petreaplus@liverpool.ac.uk

Contact information

Type(s)

Public, Scientific

Contact name

Dr PETReA Plus Trial Manager

Contact details

PETReA Plus Trial Manager, LCTC, University of Liverpool, Block C Waterhouse Building, 3
Brownlow Street
Liverpool
United Kingdom
L69 3GL
+44 (0)151 795 5289
petreaplus@liverpool.ac.uk

Type(s)

Principal investigator

Contact name

Prof Kim Linton

ORCID ID

https://orcid.org/0000-0002-3294-1548

Contact details

Chief Investigator, The University of Manchester, Cancer Research UK Manchester Institute, Wilmslow Road

Manchester United Kingdom M20 4BX

_

kim.linton@manchester.ac.uk

Additional identifiers

Integrated Research Application System (IRAS) 352809

Central Portfolio Management System (CPMS) 66722

Study information

Scientific Title

Prospective observational study of treatment & outcomes for patients with newly diagnosed follicular lymphoma

Acronym

PETReA Plus

Study objectives

Primary Objective

1) To report progression-free survival for FL by stage, grade (1-3A; 3B; transformed), tumour burden (low/high by GELF criteria) and first-line treatment.

Secondary Objective(s)

- 2) To report other clinical outcomes (treatment response rates by CT or PET-CT, duration of response, time to next treatment and overall survival) for FL by stage, grade (1-3A; 3B; transformed), tumour burden (low/high by GELF criteria) and first-line treatment
- 3) To describe first-line treatments for FL and associated patient characteristics (age, ECOG, CIRS-G score, etc) and disease characteristics (stage, grade, tumour burden, etc.)
- 4) To describe second line treatments for relapsed FL as well as associated clinical outcomes (response rates, duration of response, progression free survival, time to next treatment and overall survival), patient and disease characteristics of early treatment failure, defined as PR/SD /PD as best response to first line therapy (+/- consolidation or maintenance) or disease progression within 24 months (POD24) of initiating any first line treatment)
- 5) To report rates of initiation and completion of maintenance anti-CD20 antibody therapy, reasons for discontinuation and clinical outcomes by number of maintenance cycles
- 6) To describe the use of PET for initial staging and response assessment in standard care
- 7) To report the rate of high-grade transformation after first-line treatment in PET-staged FL, as well as clinical outcomes, patient and disease characteristics
- 8) To report serious adverse events and grade 3 adverse events related to clinical treatment (recorded but not reported in real time)
- 9) To report the patient experience using quality of life questionnaires
- 10) To report reasons for ineligibility for the main PETReA trial whilst this remains open to recruitment

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 30/04/2025, East of England- Cambridge East Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; -; CambridgeEastREC@hra.nhs.uk), ref: 25/EE/0092

Study design

Observational cohort study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Interventions

PETREA Plus will enrol all newly diagnosed follicular lymphoma patients receiving any first treatment as part of their normal care. This is an observational study which will collect data during the clinical care of the study participants. Except for Quality of Life (QOL) questionnaires provided as Patient Reported Outcome Measures (PROMs), no extra tests or assessments will be carried out over and above standard care. The study aims to collect all the required information during the participants' planned clinic visits, where available. Routinely collected information can be taken from the participant's medical notes into the case report form once the participant has consented. Data will be collected from the participants before treatment starts, at the end of treatment and during a follow-up period (6 months +/- 2 months). There are no investigational treatments, extra risks or benefits to taking part in the study. Doctors are asked to offer participation in the PETREA Plus study to all patients who are not in the PETREA trial for as long as this remains open and thereafter to all newly diagnosed FL patients, including those participating in another CTIMP/non-CTIMP trial at local PI discretion, as long as this doesn't impact the PETREA Plus study or eligibility/conduct of the other trial.

Data from the PETREA Plus study will be collected along with data from the PETREA trial, to produce a combined dataset of up to 1500 participants that could provide more information on people with high tumour burden symptomatic FL who normally have a poor chance of survival.

If willing, PETREA Plus participants will also be invited to consent to share their data with the Follicular Lymphoma Foundation Registry, for an international, observational study in follicular lymphoma, which will collect data from previously treated and untreated patients to improve how quickly new treatments are made available and to standardise treatment and care for patients across all clinics and hospitals. If willing, participants can also consent at a later date for the future collection of their routinely collected tumour tissue for future ethically approved research. These would be stored at the UK Blood Cancer Biobank.

Intervention Type

Other

Primary outcome(s)

Progression-free survival, measured using data collected from the patients' medical records, will be assessed from patient consent before the start of first-line active treatment to follow-up every 6 months until death or study end (patients who do not die will be censored at the date they were last known alive)

Key secondary outcome(s))

- 1. Anatomical response will be measured using CT scan-reported results collected from patient medical records, post-treatment.
- 2. Metabolic response will be measured using PET CT scan reported results (if performed) collected from patient's medical records, post-treatment.
- 3. Duration of response for each treatment received will be measured using data collected from patient medical records, from the start of active treatment to follow-up every 6 months until documentation of relapse, progression, high-grade transformation, start date of next line therapy, death or study end (patients who do not die will be censored at the date they were last known alive).
- 4. Progression-free survival will be measured using data collected from patient medical records, from patient consent prior to start of second-line active treatment to follow-up every 6 months until death or study end (patients who do not die will be censored at the date they were last known alive).
- 5. Time to next treatment will be measured using data collected from patient medical records, from day 1 of the last cycle of systemic induction therapy (or maintenance therapy if given), or last dose of radiotherapy to next treatment or death (patients who do not die will be censored at the date they were last known alive).
- 6. Time to next chemotherapy will be measured using data collected from patient medical records, from day 1 of the last cycle of systemic induction therapy (or maintenance therapy if given), or last dose of radiotherapy to next treatment or death (patients who do not die will be censored at the date they were last known alive).
- 7. Overall survival will be measured using data collected from patient medical records, from the date of diagnosis to the date of death from any cause (patients who do not die will be censored at the date they were last known alive).
- 8. First-line induction treatment will be measured using data collected from patient medical records at the start of active treatment.
- 9. Maintenance treatment will be measured using data collected from patient medical records, post-induction and during maintenance.
- 10. Use of PET-CT will be measured using data collected from patient medical records, at baseline staging and end of induction, consolidation, and maintenance treatment response assessment.
- 11. High-grade transformation will be measured using CT scan-reported results collected from patient medical records, from baseline data collection to follow-up every 6 months until study end.
- 12. Serious adverse events and grade 3 related adverse events will be measured using data collected from patient medical records, from the start of treatment to 30 days post-treatment.
- 13. Quality of life (QoL) will be measured using patient-completed QoL questionnaires (FACT-Lym, EQ-5D-5L, QLQ-C30), at start of treatment, post-treatment, and follow-up every 6 months until study end.
- 14. Reasons for consent decline and screen failure for PETReA trial will be measured using data collected from patients (if willing) to indicate a reason, during screening/consent discussion.

Completion date

Eligibility

Key inclusion criteria

- 1. > = 18 years of age at the time of consent
- 2. Grade 1, 2, 3A or 3B FL, or FL with histologically confirmed/clinically suspected high-grade transformation at initial presentation (de novo transformed FL)
- 3. Diagnostic biopsy performed within the last 6 months prior to study consent
- 4. Any first-line treatment planned (radiotherapy, immunotherapy, immunochemotherapy) or patients planned for initial watch and wait (these patients will have baseline data collection initially and further data will be collected if treatment (including rituximab monotherapy) starts within the study period. For patients that have already started watch and wait or treatment they can be enrolled for retrospective data collection as long as they have only received 1-2 cycles of treatment or are within one month of initiating watch and wait/treatment).
- 5. Able to provide written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

Λ

Key exclusion criteria

- 1. Patients enrolled on the PETReA trial. Patients enrolled on another IMP/intervention trial may be included in PETReA Plus as long as they adhere to the inclusion/exclusion of the trial they are enrolled on.
- 2. Any prior treatment for follicular lymphoma or transformed follicular lymphoma (except steroids)
- 3. Pregnant or lactating females
- 4. Any serious medical condition or other reason that would prevent the subject from participating in the study in the opinion of the treating physician or investigator.

Date of first enrolment

01/11/2025

Date of final enrolment

29/02/2028

Locations

Countries of recruitment

United Kingdom

England

Northern Ireland

Scotland

Wales

Study participating centre Southampton

Southampton General Hospital Tremona Road Southampton England SO16 6YD

Study participating centre Arrow Park Hospital

Arrowe Park Hospital Arrowe Park Road Wirral England CH49 5PE

Study participating centre Clatterbridge Hospital

Clatterbridge Road Wirral England CH63 4JY

Study participating centre Derriford Hospital

Derriford Road Derriford Plymouth England PL6 8DH

Study participating centre

Kent and Canterbury Hospital

Ethelbert Road Canterbury England CT1 3NG

Study participating centre Northern General Hospital

Northern General Hospital NHS Trust C Floor, Huntsmnan Building Herries Road Sheffield England S5 7AU

Study participating centre John Radcliffe Hospital

Headley Way Headington Oxford England OX3 9DU

Study participating centre Croydon University Hospital

London Road Croydon England CR7 7YE

Study participating centre Forth Vallev

Carseview House The Castle Business Park Stirling Scotland FK9 4SW

Study participating centre Poole Hospital Longfleet Road

Poole England BH15 2JB

Study participating centre Taunton

Musgrove Park Hospital Taunton England TA1 5DA

Study participating centre Leicester Royal Infirmary

Infirmary Square Leicester England LE1 5WW

Study participating centre University College London Hospitals NHS Foundation Trust

250 Euston Road London England NW1 2PG

Study participating centre The Royal London Hospital

80 Newark Street London England E1 2ES

Study participating centre Betsi Cadwaladr University Lhb

Executive Offices, Ysbyty Gwynedd Penrhosgarnedd Bangor Wales LL57 2PW

Study participating centre East Suffolk and North Essex NHS Foundation Trust

Colchester Dist General Hospital Turner Road Colchester England CO4 5JL

Study participating centre The Christie NHS Foundation Trust

550 Wilmslow Road Withington Manchester England M20 4BX

Study participating centre Blackpool Teaching Hospitals NHS Foundation Trust

Victoria Hospital Whinney Heys Road Blackpool England FY3 8NR

Study participating centre Gartnavel Royal Hospital

1055 Great Western Road Glasgow Scotland G12 0XH

Study participating centre Guy's and St Thomas' NHS Foundation Trust

St Thomas' Hospital Westminster Bridge Road London England SE1 7EH

Study participating centre

Belfast City Hospital

51 Lisburn Rd Belfast Northern Ireland BT9 7AB

Study participating centre University Hospitals Birmingham NHS Foundation Trust

Queen Elizabeth Hospital Mindelsohn Way Edgbaston Birmingham England B15 2GW

Study participating centre Sandwell Health Campus

_

West Bromwich England B71 4HJ

Study participating centre Milton Keynes University Hospital

Milton Keynes Hospital Standing Way Eaglestone Milton Keynes England MK6 5LD

Study participating centre Salford Royal Hospital

Stott Lane Salford England M6 8HD

Study participating centre Royal Cornwall Hospital (treliske)

Treliske

Truro England TR1 3LJ

Study participating centre Russells Hall Hospital

Pensnett Road
Dudley
England
DY1 2HQ

Study participating centre Queens Hospital

Belvedere Road Burton-on-trent England DE13 0RB

Study participating centre Peterborough City Hospital

Edith Cavell Campus Bretton Gate Bretton Peterborough England PE3 9GZ

Study participating centre Hinchingbrooke Hospital

Hinchingbrooke Park Huntingdon England PE29 6NT

Study participating centre The Royal Oldham Hospital

Rochdale Road Oldham England OL1 2JH

Study participating centre Pilgrim Hospital

Sibsey Road Boston England PE21 9QS

Study participating centre Lincoln County Hospital

Greetwell Road Lincoln England LN2 5QY

Study participating centre Good Hope Hospital

Rectory Road Sutton Coldfield England B75 7RR

Study participating centre Hywel Dda University Health Board

Ystwyth Building, St David's Park, Job's Well Road Carmarthen Wales SA31 3BB

Study participating centre West Middlesex University Hospital

Twickenham Road Isleworth England TW7 6AF

Study participating centre Queen Alexandra Hospital

Southwick Hill Road Cosham Portsmouth England PO6 3LY

Study participating centre Nottingham City Hospital

Hucknall Road Nottingham England NG5 1PB

Study participating centre St Helier Hospital

Wrythe Lane Carshalton, Surrey England SM5 1AA

Study participating centre Barnet & Chase Farm Hospitals

127 The Ridgeway Enfield England EN2 8JL

Study participating centre University Hospital of Wales

Heath Park Cardiff Wales CF14 4XW

Study participating centre Grantham and District Hospital

101 Manthorpe Road Grantham England NG31 8DG

Sponsor information

Organisation

University of Liverpool

ROR

https://ror.org/04xs57h96

Funder(s)

Funder type

Charity

Funder Name

The Follicular Lymphoma Foundation

Funder Name

Blood Cancer UK

Funder Name

The Joyce & Norman Freed Charitable Trust

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes